Stammler R, Anglicheau D, Landi B, Meatchi T, Ragot E, Thervet E, Lazareth H. Gastrointestinal tumors in transplantation: Two case reports and review of literature . World J Gastroenterol 2022; 28(34): 5076-5085 [PMID: 36160649 DOI: 10.3748/wjg.v28.i34.5076]
Corresponding Author of This Article
Hélène Lazareth, MD, PhD, Doctor, Department of Nephrology, Georges Pompidou European Hospital, 20, rue Leblanc, Paris 75015, France. helene.lazareth@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 14, 2022; 28(34): 5076-5085 Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.5076
Gastrointestinal tumors in transplantation: Two case reports and review of literature
Romain Stammler, Dany Anglicheau, Bruno Landi, Tchao Meatchi, Emilia Ragot, Eric Thervet, Hélène Lazareth
Romain Stammler, Eric Thervet, Hélène Lazareth, Department of Nephrology, Georges Pompidou European Hospital, Paris 75015, France
Dany Anglicheau, Department of Renal Transplantation, Necker-Enfants Malades Institute, French National Institutes of Health and Medical Research U1151, Paris 75015, France
Dany Anglicheau, Bruno Landi, Eric Thervet, Hélène Lazareth, Université Paris Cité, Assistance Publique des Hôpitaux de Paris, Paris 75001, France
Bruno Landi, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Paris 75015, France
Tchao Meatchi, Department of Pathology, Georges Pompidou European Hospital, Paris 75015, France
Emilia Ragot, Department of Digestive Surgery, Georges Pompidou European Hospital, Paris 75015, France
Author contributions: Stammler R and Lazareth H designed the study; Stammler R, Lazareth H, Anglicheau D, Meatchi T, Ragot E, and Thervet E investigated the patients and collected the data; Stammler R, Lazareth H, and Landi B interpreted the data and wrote the manuscript; all authors revised the manuscript and approved the final version.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Conflict-of-interest statement: The authors have no conflicts of interest to report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hélène Lazareth, MD, PhD, Doctor, Department of Nephrology, Georges Pompidou European Hospital, 20, rue Leblanc, Paris 75015, France. helene.lazareth@gmail.com
Received: March 7, 2022 Peer-review started: March 7, 2022 First decision: April 5, 2022 Revised: April 19, 2022 Accepted: August 6, 2022 Article in press: August 6, 2022 Published online: September 14, 2022 Processing time: 183 Days and 22.5 Hours
Abstract
BACKGROUND
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. As most of them harbor a KIT mutation (75%), selective kinase inhibitors are the therapeutic option and show a sustained objective response among patients with metastatic or unresectable GISTs. A well-known higher risk of neoplasm has been described among renal transplant recipients (RTRs). Nevertheless, only few cases of GIST onset among transplant patients have been reported in the literature.
CASE SUMMARY
Here, we describe 2 cases of gastric GIST occurring during the follow-up of RTRs. We also review the existing literature concerning GIST occurrence in transplant patients. In total and in association with our 2 cases, 16 patients have been reported. The median age was 59.5 years and 69% were male. With a median tumor size of 45 mm, no patient displayed metastatic dissemination at diagnosis. Time from transplantation to diagnosis was highly variable between 5 mo and 21 years. Histopathological data mostly revealed high risk of progression (43%). Death increased to 29% during follow-up. Surgical treatment was systematically performed when the tumor was operable (94%). The use of adjuvant therapy was uncommon (19%).
CONCLUSION
GISTs represent rare but potentially severe malignant complication among transplant patients.
Core Tip: Although a well-known higher risk of neoplasm has been described among renal transplant recipients (RTRs), few cases of gastrointestinal stromal tumors (GISTs) have been reported. We describe 2 cases of gastric GIST among RTRs and provide a review of the literature. We report 16 patients with a median age of 59.5 years, and 69% were male. No patient displayed metastasis at diagnosis. Time from transplantation to diagnosis varied between 5 mo and 21 years. Histopathology revealed high risk of progression (43%). Death increased to 29%. Surgical treatment was commonly performed (94%). The use of adjuvant therapy was uncommon (19%).
